RHYTHM PHARMACEUTICALS INC (RYTM) Fundamental Analysis & Valuation

NASDAQ:RYTM • US76243J1051

Current stock price

87.72 USD
-0.97 (-1.09%)
At close:
87.72 USD
0 (0%)
After Hours:

This RYTM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. RYTM Profitability Analysis

1.1 Basic Checks

  • In the past year RYTM has reported negative net income.
  • In the past year RYTM has reported a negative cash flow from operations.
  • In the past 5 years RYTM always reported negative net income.
  • RYTM had a negative operating cash flow in each of the past 5 years.
RYTM Yearly Net Income VS EBIT VS OCF VS FCFRYTM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • RYTM has a Return On Assets (-42.05%) which is in line with its industry peers.
  • RYTM's Return On Equity of -74.78% is in line compared to the rest of the industry. RYTM outperforms 50.00% of its industry peers.
Industry RankSector Rank
ROA -42.05%
ROE -74.78%
ROIC N/A
ROA(3y)-55%
ROA(5y)-46.69%
ROE(3y)-114.78%
ROE(5y)-87.47%
ROIC(3y)N/A
ROIC(5y)N/A
RYTM Yearly ROA, ROE, ROICRYTM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • RYTM's Gross Margin of 89.73% is amongst the best of the industry. RYTM outperforms 91.47% of its industry peers.
  • In the last couple of years the Gross Margin of RYTM has remained more or less at the same level.
  • RYTM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.46%
GM growth 5YN/A
RYTM Yearly Profit, Operating, Gross MarginsRYTM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. RYTM Health Analysis

2.1 Basic Checks

  • RYTM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RYTM has more shares outstanding
  • RYTM has more shares outstanding than it did 5 years ago.
  • RYTM has a better debt/assets ratio than last year.
RYTM Yearly Shares OutstandingRYTM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
RYTM Yearly Total Debt VS Total AssetsRYTM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • RYTM has an Altman-Z score of 13.14. This indicates that RYTM is financially healthy and has little risk of bankruptcy at the moment.
  • RYTM's Altman-Z score of 13.14 is amongst the best of the industry. RYTM outperforms 84.11% of its industry peers.
  • RYTM has a Debt/Equity ratio of 0.37. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.37, RYTM is not doing good in the industry: 69.96% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Altman-Z 13.14
ROIC/WACCN/A
WACC9.5%
RYTM Yearly LT Debt VS Equity VS FCFRYTM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • RYTM has a Current Ratio of 4.41. This indicates that RYTM is financially healthy and has no problem in meeting its short term obligations.
  • RYTM has a Current ratio (4.41) which is comparable to the rest of the industry.
  • A Quick Ratio of 4.16 indicates that RYTM has no problem at all paying its short term obligations.
  • RYTM's Quick ratio of 4.16 is in line compared to the rest of the industry. RYTM outperforms 51.55% of its industry peers.
Industry RankSector Rank
Current Ratio 4.41
Quick Ratio 4.16
RYTM Yearly Current Assets VS Current LiabilitesRYTM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. RYTM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 30.73% over the past year.
  • The Revenue has grown by 21.57% in the past year. This is a very strong growth!
  • The Revenue has been growing by 100.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)30.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.39%
Revenue 1Y (TTM)21.57%
Revenue growth 3Y100.22%
Revenue growth 5YN/A
Sales Q2Q%36.87%

3.2 Future

  • Based on estimates for the next years, RYTM will show a very strong growth in Earnings Per Share. The EPS will grow by 43.42% on average per year.
  • RYTM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 61.38% yearly.
EPS Next Y-3.01%
EPS Next 2Y33.66%
EPS Next 3Y46.71%
EPS Next 5Y43.42%
Revenue Next Year53.93%
Revenue Next 2Y69.23%
Revenue Next 3Y66.81%
Revenue Next 5Y61.38%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RYTM Yearly Revenue VS EstimatesRYTM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
RYTM Yearly EPS VS EstimatesRYTM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

1

4. RYTM Valuation Analysis

4.1 Price/Earnings Ratio

  • RYTM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year RYTM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RYTM Price Earnings VS Forward Price EarningsRYTM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RYTM Per share dataRYTM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • RYTM's earnings are expected to grow with 46.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.66%
EPS Next 3Y46.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RYTM Dividend Analysis

5.1 Amount

  • RYTM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RYTM Fundamentals: All Metrics, Ratios and Statistics

RHYTHM PHARMACEUTICALS INC

NASDAQ:RYTM (4/20/2026, 8:00:02 PM)

After market: 87.72 0 (0%)

87.72

-0.97 (-1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-09
Earnings (Next)05-05
Inst Owners104.84%
Inst Owner Change0.01%
Ins Owners0.78%
Ins Owner Change1.22%
Market Cap5.99B
Revenue(TTM)189.76M
Net Income(TTM)-201.92M
Analysts85.45
Price Target140.01 (59.61%)
Short Float %11.74%
Short Ratio8.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.92%
Min EPS beat(2)-11.05%
Max EPS beat(2)12.89%
EPS beat(4)1
Avg EPS beat(4)-5.05%
Min EPS beat(4)-13.18%
Max EPS beat(4)12.89%
EPS beat(8)4
Avg EPS beat(8)-1.22%
EPS beat(12)6
Avg EPS beat(12)-0.81%
EPS beat(16)9
Avg EPS beat(16)1.78%
Revenue beat(2)1
Avg Revenue beat(2)0.6%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)2.02%
Revenue beat(4)2
Avg Revenue beat(4)-2.57%
Min Revenue beat(4)-20.47%
Max Revenue beat(4)8.98%
Revenue beat(8)4
Avg Revenue beat(8)-1.22%
Revenue beat(12)5
Avg Revenue beat(12)0.12%
Revenue beat(16)7
Avg Revenue beat(16)13.77%
PT rev (1m)-1.82%
PT rev (3m)-0.72%
EPS NQ rev (1m)-1.5%
EPS NQ rev (3m)-9.3%
EPS NY rev (1m)-3.89%
EPS NY rev (3m)-16.4%
Revenue NQ rev (1m)-2.07%
Revenue NQ rev (3m)-5.09%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)-1.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.57
P/FCF N/A
P/OCF N/A
P/B 22.18
P/tB 22.63
EV/EBITDA N/A
EPS(TTM)-3.11
EYN/A
EPS(NY)-3.2
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS2.78
BVpS3.95
TBVpS3.88
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -42.05%
ROE -74.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.73%
FCFM N/A
ROA(3y)-55%
ROA(5y)-46.69%
ROE(3y)-114.78%
ROE(5y)-87.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.46%
GM growth 5YN/A
F-Score5
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.23%
Cap/Sales 0.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.41
Quick Ratio 4.16
Altman-Z 13.14
F-Score5
WACC9.5%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.39%
EPS Next Y-3.01%
EPS Next 2Y33.66%
EPS Next 3Y46.71%
EPS Next 5Y43.42%
Revenue 1Y (TTM)21.57%
Revenue growth 3Y100.22%
Revenue growth 5YN/A
Sales Q2Q%36.87%
Revenue Next Year53.93%
Revenue Next 2Y69.23%
Revenue Next 3Y66.81%
Revenue Next 5Y61.38%
EBIT growth 1Y52.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.42%
EBIT Next 3Y44.33%
EBIT Next 5YN/A
FCF growth 1Y-2.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.58%
OCF growth 3YN/A
OCF growth 5YN/A

RHYTHM PHARMACEUTICALS INC / RYTM Fundamental Analysis FAQ

What is the fundamental rating for RYTM stock?

ChartMill assigns a fundamental rating of 4 / 10 to RYTM.


What is the valuation status of RHYTHM PHARMACEUTICALS INC (RYTM) stock?

ChartMill assigns a valuation rating of 1 / 10 to RHYTHM PHARMACEUTICALS INC (RYTM). This can be considered as Overvalued.


Can you provide the profitability details for RHYTHM PHARMACEUTICALS INC?

RHYTHM PHARMACEUTICALS INC (RYTM) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for RYTM stock?

The Earnings per Share (EPS) of RHYTHM PHARMACEUTICALS INC (RYTM) is expected to decline by -3.01% in the next year.